Vitiligo is a common, acquired skin disease with an estimated incidence of 0.5%–1%. It is characterized by circumscribed macules of amelanosis caused by destruction of the melanocytes. In the pathogenesis of this disorder, the autoimmune, the neural, and the self-destructive hypotheses are well known. The process may be localized to one circumscribed area, or it may be distributed symmetrically on the trunk and the extremities, although a very extensive type may also develop.

Treatement options such as psoralen-ultraviolet A (PUVA) therapy, steroid cream locally, and pigment-cell transplantation techniques are aimed at creating repigmentation. In very extensive vitiligo, repigmentation therapy is seldom effective. The remaining pigmented patches may cause serious psychologic problems, especially in patients with a dark skin. Such pigmented areas can be removed by using a depigmentation cream for between 6 and 12 months. Unfortunately, in some cases the bleaching cream fails to cause any depigmentation and severe irritation of the skin has often been reported. Recently, for depigmentation, we have used a Ruby laser that is capable of selectively destroying melanocytes.

**Materials and methods**

Eight healthy vitiligo patients (five women and three men, aged between 10 and 69 years) with residual pigmentation on the hands, arms, and face, were treated once with a Q-Switched Ruby laser, Lambda type (694 nm). All patients had been treated before with a bleaching cream containing 4-methoxyphenol, but without success.

**Study design**

The study was an open, noncomparative clinical trial to evaluate the efficacy and safety of depigmentation using Ruby laser treatment. Patients were asked to fill out a questionnaire which included age on onset of vitiligo, provoking factors, family history, and work history. Informed written consent was obtained from each person.

The patients were treated once with energy densities varying from 10 to 40 J/cm², according to skin type. Treated skin was covered with sterile gauze and patients were told to avoid exposure to sunlight for 6 weeks. Follow-up visits took place at 3, 6, and 9 months after treatment.

**Results**

The mean age of the patients was 32.8 years and the mean duration of the disease was 14.5 years. Depigmentation was obvious within 7 days in all subjects. The treatment was painful in four patients; there were no other significant
adverse events. During a follow up period of 9 months, follicular depigmentation developed in five patients. This was probably related to migration to the surface of residual melanocytes that had been localized in the epidermal appendages. In three patients, who also mentioned a positive Koebner phenomenon in the questionnaire, the treated areas remained depigmented (Fig. 1). Table 1 summarizes the main results.

**Discussion**

When none of the therapy options for repigmentation in patients with vitiligo are successful and the skin has already become over 80% depigmented, both dermatologist and patient may decide to attempt to remove the remaining pigmentation. In general, this is a point of no return. Protection from the sun will be necessary for the rest of the patient’s life.4

**Figure 1** Left and right arm of patient 3 (Table 1): (a) before laser treatment, (b) after laser treatment

**Table 1** History of vitiligo and results of laser therapy in the treated study cases

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Sex</th>
<th>Age at onset</th>
<th>Koebner Phenomenon</th>
<th>Autoimmune Disease</th>
<th>Laser treatment results</th>
<th>Side-effects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Depigmentation</td>
<td>Pain</td>
</tr>
<tr>
<td>1</td>
<td>14</td>
<td>M</td>
<td>4</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>46</td>
<td>M</td>
<td>38</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>3</td>
<td>20</td>
<td>W</td>
<td>12</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>30</td>
<td>W</td>
<td>15</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>5</td>
<td>10</td>
<td>W</td>
<td>4</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>6</td>
<td>36</td>
<td>W</td>
<td>4</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>7</td>
<td>69</td>
<td>W</td>
<td>45</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>8</td>
<td>38</td>
<td>M</td>
<td>25</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
</tbody>
</table>

© 1997 Blackwell Science Ltd

*International Journal of Dermatology 1997, 36, 386–388*
Destroying the melanocytes in the residual pigmentation is possible by the daily use locally of the bleaching substance 4-methoxyphenol or the monobenzylether of hydroquinone. A small fraction of the cream will reach the bloodstream after transcutaneous uptake; thus there is a risk of damage to other melanocyte-containing structures (e.g., eyes and neurocutaneous structures) and all types of collagen. To minimize this risk the cream should be applied in small amounts. Side-effects such as severe redness, burning, and itching often occur. It is obvious that depigmentation is not easy to achieve.

We have attempted to destroy melanocytes by using a Q-switched Ruby laser. The lightbeam, with a wavelength in the red region, is capable of penetrating deep into the dermal layer. The coefficient of absorption of the melanin chromophore is high for laser-light at a wavelength of 694 nm (Fig. 2). Because the duration of the energy pulse is shorter than the thermal relaxation time of melanosomes, no energy (i.e., heat) will be transduced into the surrounding tissue. Further cell damage and scar formation will rarely be seen.

Only the three patients who mentioned a positive Koebner phenomenon remained depigmented after laser therapy. Laser treatment can also be considered as a stimulus to induce the Koebner phenomenon. This aspect could be important in deciding whether to produce depigmentation in the patient by laser therapy.

Conclusions

Compared with bleaching of the skin with a local depigmentation cream, laser therapy is effective after a single treatment and shows no persistent side-effects.

References